Adjunct dapagliflozin treatment improves glycemic control in patients with type 1 diabetes
Addition of dapagliflozin to intensive insulin therapy in adults with type 1 diabetes who had suboptimal glycemic control reduced blood glucose, aided in weight loss and led to a reduction in insulin doses. However, it also slightly increased the risk of diabetic ketoacidosis risk. These findings from the DEPICT-2 Study were presented June 24, 2018 at the American Diabetes Association’s 78th Scientific Sessions in Orlando, Florida.
To continue reading this article
Continue reading your article with a eMediNexus account.